Yu Kato

3.4k total citations · 4 hit papers
30 papers, 2.7k citations indexed

About

Yu Kato is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Yu Kato has authored 30 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 14 papers in Immunology and 9 papers in Molecular Biology. Recurrent topics in Yu Kato's work include Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (7 papers). Yu Kato is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (7 papers). Yu Kato collaborates with scholars based in Japan, United States and United Kingdom. Yu Kato's co-authors include Tasuku Honjo, Taku Okazaki, Takanori Kitamura, Jeffrey W. Pollard, Luca Cassetta, Kenji Kabashima, Motonobu Nakamura, Hiroaki Yagi, Y. Tokura and Ryosuke Hino and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Yu Kato

27 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

2010 537 citations Yu Kato, Tasuku Honjo et al. profile →
CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages

2015 509 citations Takanori Kitamura, Daniel Soong et al. The Journal of Experimental Medicine profile →
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

2019 341 citations Yu Kato, Kimiyo Tabata et al. PLoS ONE profile →
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

2011 255 citations Taku Okazaki, Il‐mi Okazaki et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yu Kato Japan	15	1.8k	1.5k	472	348	262	30	2.7k
Yibei Zhu China	27	1.8k 1.0×	2.1k 1.4×	538 1.1×	362 1.0×	141 0.5×	55	3.1k
Orianne Colussi France	6	1.2k 0.7×	741 0.5×	475 1.0×	415 1.2×	201 0.8×	10	1.8k
Valerie Chew Singapore	19	1.3k 0.7×	1.2k 0.8×	491 1.0×	390 1.1×	545 2.1×	37	2.4k
Xiang‐Ming Lao China	26	1.0k 0.6×	1.1k 0.7×	401 0.8×	295 0.8×	418 1.6×	56	2.1k
Ursina Teitelbaum United States	19	1.9k 1.1×	1.2k 0.8×	596 1.3×	279 0.8×	105 0.4×	54	2.7k
Shuang‐Jian Qiu China	22	1.9k 1.1×	1.9k 1.3×	607 1.3×	341 1.0×	570 2.2×	35	3.2k
Alice Pons United States	5	2.4k 1.4×	1.3k 0.9×	411 0.9×	668 1.9×	64 0.2×	8	2.8k
Ann Cleverly United States	25	1.5k 0.9×	530 0.4×	1.3k 2.8×	333 1.0×	193 0.7×	54	2.6k
Elizabeth Stankevich United States	15	2.4k 1.4×	1.3k 0.9×	416 0.9×	665 1.9×	75 0.3×	39	2.9k
Colm R. Duffy United States	4	1.6k 0.9×	1.1k 0.8×	514 1.1×	394 1.1×	46 0.2×	11	2.3k

Countries citing papers authored by Yu Kato

Since Specialization

Citations

This map shows the geographic impact of Yu Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Kato more than expected).

Fields of papers citing papers by Yu Kato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Kato. The network helps show where Yu Kato may publish in the future.

Co-authorship network of co-authors of Yu Kato

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Kato. A scholar is included among the top collaborators of Yu Kato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Kato. Yu Kato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malki, Monzr M. Al, Mark Juckett, Miguel‐Angel Perales, et al.. (2025). A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability of TRX103 Cell Infusion in Subjects with Hematological Malignancies Undergoing HLA-Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT).. Transplantation and Cellular Therapy. 31(2). S291–S291.

Ozawa, Yoichi, et al.. (2025). Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine. Cancer Research Communications. 5(3). 398–408.

Kato, Yu. (2025). Lenvatinib enhances antitumor immunity of anti-PD-1 antibody. International Journal of Clinical Oncology. 30(4). 666–673. 1 indexed citations

Kato, Yu, Yoichi Ozawa, Yusuke Adachi, et al.. (2023). Abstract 5124: The effect of lenvatinib in combination with chemotherapy plus immune checkpoint inhibitors on tumor microenvironments in the mouse syngeneic tumor model. Cancer Research. 83(7_Supplement). 5124–5124. 1 indexed citations

Inoue, Satoshi, Yoshinobu Yamane, Shuntaro Tsukamoto, et al.. (2021). Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors. Bioorganic & Medicinal Chemistry Letters. 48. 128247–128247. 5 indexed citations

Inoue, Satoshi, Yoshinobu Yamane, Shuntaro Tsukamoto, et al.. (2021). Discovery of a potent and selective Axl inhibitor in preclinical model. Bioorganic & Medicinal Chemistry. 39. 116137–116137. 6 indexed citations

Kitamura, Takanori, Yu Kato, Demi Brownlie, et al.. (2019). Mammary Tumor Cells with High Metastatic Potential Are Hypersensitive to Macrophage-Derived HGF. Cancer Immunology Research. 7(12). 2052–2064. 14 indexed citations

Kato, Yu, Kimiyo Tabata, Takayuki Kimura, et al.. (2019). Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE. 14(2). e0212513–e0212513. 341 indexed citations breakdown →

Kitamura, Takanori, Luca Cassetta, Stamatina Fragkogianni, et al.. (2018). Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer. Frontiers in Immunology. 8. 2004–2004. 119 indexed citations

10.

Kato, Yu, Xiaoyi Bao, Kimiyo Tabata, et al.. (2016). Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Annals of Oncology. 27. vi1–vi1. 33 indexed citations

11.

Rodríguez-Tirado, Carolina, et al.. (2016). Long-term High-Resolution Intravital Microscopy in the Lung with a Vacuum Stabilized Imaging Window. Journal of Visualized Experiments. 26 indexed citations

12.

Entenberg, David, Carolina Rodríguez-Tirado, Yu Kato, et al.. (2015). In vivosubcellular resolution optical imaging in the lung reveals early metastatic proliferation and motility. PubMed. 4(3). 1–11. 54 indexed citations

13.

Kato, Yu, Kimiyo Tabata, Yusaku Hori, et al.. (2015). Abstract A92: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors. Molecular Cancer Therapeutics. 14(12_Supplement_2). A92–A92. 13 indexed citations

14.

Nakagawa, Takayuki, Tomohiro Matsushima, Satoshi Kawano, et al.. (2014). Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway‐induced resistance to vascular endothelial growth factor receptor inhibitor. Cancer Science. 105(6). 723–730. 32 indexed citations

15.

Okazaki, Taku, Il‐mi Okazaki, Jian Wang, et al.. (2011). PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. The Journal of Experimental Medicine. 208(2). 395–407. 255 indexed citations breakdown →

16.

Wang, Jian, Il‐mi Okazaki, Taku Yoshida, et al.. (2010). PD-1 deficiency results in the development of fatal myocarditis in MRL mice. International Immunology. 22(6). 443–452. 220 indexed citations

17.

Jiang, Fang, Taku Yoshida, Fumio Nakaki, et al.. (2009). Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1-/- mice. International Immunology. 21(5). 499–509. 8 indexed citations

18.

Kato, Yu, Yoshimasa Tanaka, Mikihito Hayashi, Katsuya Okawa, & Nagahiro Minato. (2006). Involvement of CD166 in the Activation of Human γδT Cells by Tumor Cells Sensitized with Nonpeptide Antigens. The Journal of Immunology. 177(2). 877–884. 43 indexed citations

19.

Kato, Yu, et al.. (2003). Requirement of Species-Specific Interactions for the Activation of Human γδ T Cells by Pamidronate. The Journal of Immunology. 170(7). 3608–3613. 75 indexed citations

20.

Kato, Yu, et al.. (2001). Targeting of Tumor Cells for Human γδ T Cells by Nonpeptide Antigens. The Journal of Immunology. 167(9). 5092–5098. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact